Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer
NCT00049231 · View on ClinicalTrials.gov ↗
Study Summary
RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 may be effective in measuring oxygen in tumor tissue and helping to predict the effectiveness of anticancer therapy. PURPOSE: Diagnostic trial to study the effectiveness of EF5 in detecting tumor hypoxia in patients who have stage IIB, stage IIIB, or stage IVA cervical cancer.
Conditions Studied
Interventions
- PROCEDURE biopsy
- OTHER immunohistochemistry staining method
- DRUG EF5
Study Locations (5)
Oklahoma
- Oklahoma University Medical Center — Oklahoma City
- Cancer Care Associates - Midtown Tulsa — Tulsa
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences — Little Rock
Colorado
- Colorado Gynecologic Oncology Group P.C. — Denver
Missouri
- Ellis Fischel Cancer Center at University of Missouri - Columbia — Columbia
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2005-08 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049231
The ClinicalTrials.gov registry entry for NCT00049231 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Gynecologic Oncology Group, which has 61 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 3 interventions — of which biopsy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00049231 reports 5 study locations spanning 4 distinct geographic areas — top geographies include Oklahoma, Arkansas, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00049231 about?
NCT00049231 is a clinical study titled "EF5 to Detect Tumor Hypoxia in Patients With Stage IIB, Stage IIIB, or Stage IVA Cervical Cancer". RATIONALE: Knowing the level of oxygen in tumor tissue may help predict the effectiveness of anticancer therapy. EF5 may be effective in measuring oxygen in tumor tissue and helping to predict the effectiveness of anticancer therapy. PURPOSE: Diagnostic trial to study the effectiveness of EF5 in de...
What is the current status of trial NCT00049231?
This trial is currently completed. It is a NA study. The study started on 2003-06. Estimated completion is 2005-08.
What conditions does trial NCT00049231 study?
This clinical trial studies the following conditions: Cervical Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00049231?
The interventions under investigation include: biopsy (PROCEDURE), immunohistochemistry staining method (OTHER), EF5 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00049231?
This trial is sponsored by Gynecologic Oncology Group, which has 61 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00049231 being conducted?
This trial has 5 study locations across Arkansas, Colorado, Missouri, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.